You’re specifying air handling for a cGMP facility, you pull up the regulation, and you find that the entire federal requirement for dust control fits in four short paragraphs — and the operative word in most of them is “adequate.” No CFM numbers. No filter grades. No equipment list. If you’ve been wondering whether you missed a more specific document somewhere, you didn’t. This is how the regulation works, and understanding why it’s written this way tells you how to comply with it.
What §211.46 actually says
Section 211.46 sits in Subpart C of the drug cGMP regulations — “Buildings and Facilities” — under the heading “Ventilation, air filtration, air heating and cooling.” Paraphrased faithfully, its four subsections require:
(a) Adequate ventilation. That’s the whole subsection — one sentence establishing the baseline obligation.
(b) Equipment for adequate control over air pressure, microorganisms, dust, humidity, and temperature — when appropriate for the manufacture, processing, packing, or holding of a drug product. Dust is named explicitly, alongside pressure control, which is why pressure cascades between rooms are a cGMP design fixture.
(c) Air filtration systems, including prefilters and particulate matter air filters, on air supplies to production areas when appropriate. Then two sentences that do a lot of work: if air is recirculated to production areas, measures must be taken to control recirculation of dust from production — and where air contamination occurs during production, there must be exhaust systems or other systems adequate to control contaminants.
(d) Air handling systems for penicillin production must be completely separate from those serving other drug products. This is the one place the regulation abandons “adequate” for an absolute.
Why “adequate” is the standard — and what it means for you
The regulation is performance-based on purpose. FDA regulates thousands of facilities making everything from aspirin to inhalation powders; a prescriptive equipment list would fit none of them well. So the burden shifts to you: your facility defines what adequate means for your products, documents the rationale, and proves the controls work. That’s not a loophole — it’s the compliance model. The question an investigator asks isn’t “do you have the required equipment?” It’s “show me your contamination control rationale, show me the equipment implementing it, and show me the data proving it performs.” Dust control that exists but isn’t documented, qualified, and monitored is — from an audit standpoint — barely better than dust control that doesn’t exist.
This is also why cross-contamination findings show up so often in FDA inspection observations. Visible dust accumulation in a production area is one of the easiest observations an investigator can write, because it’s self-evidencing: the dust on the ledge is the demonstration that control was not adequate.
The recirculation clause most specs skim past
The most consequential sentence for dust collection design hides in the middle of (c): recirculated air requires measures to control recirculation of dust from production. Read plainly, this means the return-air question — the one every facility eventually asks because conditioning make-up air in the Southwest is expensive — has a regulatory answer, not just an engineering one. You can recirculate air from dust collection in a cGMP facility, but the filtration on that return path has to be defensible: typically HEPA final filtration, integrity-testable, monitored, with the rationale written down. For potent compounds, many facilities exhaust outside anyway, because the energy savings never outweigh a contamination investigation. We walk through the general trade-offs in our return air vs. exhaust article — in a cGMP context, add §211.46(c) to that analysis as the controlling constraint.
Where dust collection fits in the compliance picture
The regulation names the outcomes; here’s how dust collection typically delivers them in powder operations — dispensing, blending, milling, granulation, compression, coating:
Capture at the source. The (c) requirement for exhaust “where air contamination occurs during production” points directly at source capture: hoods, enclosures, and pickup points at the operations generating dust, sized so particles never reach the general room air. Room-level filtration cleaning up what source capture missed is a backstop, not a strategy — by the time dust is in the room, it’s on surfaces, and surfaces are where cross-contamination findings come from.
Filtration matched to the exposure. Cartridge collectors with high-efficiency media handle most pharmaceutical powders, with HEPA final filters where air returns or where potency demands it. Bag-in/bag-out housings keep filter changes from becoming the exposure event the system exists to prevent.
Containment through the whole path. The (b) requirement for pressure control extends to the collector itself: where the system sits, which way air moves between rooms, and what happens to captured product — which in pharma is often reclaimable material with real value, not just waste.
Segregation where the rule is absolute. Penicillin’s completely-separate mandate in (d), backed by §211.176’s testing requirement, means shared ductwork or a shared collector between penicillin and anything else is not a design option at any filtration level. Beta-lactams generally get treated the same way as a matter of practice. The neighboring section, §211.42, reinforces the theme: operations happen in separately defined areas designed to prevent contamination and mix-ups.
Supplements: same logic, different part
If you manufacture dietary supplements rather than drugs, your framework is 21 CFR Part 111, and its physical-plant subpart carries the same performance-based requirements: adequate ventilation or environmental control, and design that prevents contamination between products. Herbal extracts, botanical powders, and nutraceutical manufacturing generally involve the same dust-generating operations as drug manufacture — and often dustier ones. Facilities that run both product classes, or co-pack for clients who do, simplify their lives by designing dust control to the Part 211 standard across the board: one rationale, one qualification approach, no explaining to an auditor why one room got a lower bar.
The other regulation your powder answers to
Here’s the overlap that catches facilities designed by HVAC firms without dust experience: many pharmaceutical and nutraceutical powders — lactose, starch, cellulose, sugars, and a long list of APIs — are combustible dusts, which puts your facility in scope for NFPA 660 independent of anything FDA requires. That means a dust hazard analysis (DHA) obligation, explosion protection appropriate to your dust’s characteristics, and housekeeping requirements — a parallel compliance track answering a different question. FDA asks whether dust contaminates your product; NFPA 660 asks whether it deflagrates. A collector that’s perfect for containment and wrong for explosion protection fails half its job. We coordinate the DHA and testing process and prepare the documentation your qualified engineer reviews — and a system designed with both frameworks on the table from day one costs less than retrofitting either. Our NFPA 660 checklist is the fastest way to see where your facility stands on that second track.
When this article is NOT for you
If you’re designing aseptic processing suites, sterile fill-finish, or classified cleanroom cascades, your controlling requirements go well beyond §211.46 into §211.42(c)(10) and ISO 14644 territory — that’s cleanroom engineering, and you need a firm that lives there. If you need a validation consultant to author your contamination control strategy documents, that’s also a different discipline than ours. Where we fit is the dust side: the capture, collection, and filtration equipment that your strategy documents point to — specified, sized, and installed to hold up under both the FDA and NFPA lenses.
What your facility gets from getting this right
A dust collection system designed against §211.46 from the start gives you a clean line in your contamination control rationale, an audit answer that takes one paragraph instead of one investigation, recovered product that would otherwise coat your ledges, and one system satisfying two regulators. If you’re planning a pharmaceutical or supplement facility — or fixing dust findings in one — the place to start is a walkthrough of your actual operations, and our 2026 cost guide covers what drives system cost before anyone quotes you anything.
Get a free assessment of your powder handling areas
Frequently asked questions
What does 21 CFR 211.46 require for dust control?
Adequate ventilation; equipment controlling air pressure, microorganisms, dust, humidity, and temperature when appropriate; air filtration on production air supplies when appropriate; dust control on recirculated air; exhaust or equivalent systems where contamination occurs during production; and completely separate air handling for penicillin.
Does FDA require dust collection systems by name?
No — the regulation is performance-based. In practice, source-capture dust collection is the standard way powder operations meet the exhaust and contamination-control requirements, and what FDA audits is whether your controls demonstrably work.
Can we recirculate air from dust collection?
Yes, if you take measures to control recirculated dust — in practice, defensible final filtration (typically HEPA), integrity monitoring, and a documented rationale. Penicillin areas can never share air handling with other products.
Why is penicillin treated differently?
Trace penicillin exposure can trigger severe allergic reactions, so §211.46(d) requires completely separate air handling and §211.176 requires testing other products where exposure is possible.
Do supplement manufacturers follow this section?
Supplements fall under 21 CFR Part 111, which carries parallel physical-plant requirements. Facilities running both product classes usually design to the Part 211 standard throughout.
Are pharmaceutical powders combustible dust?
Many are — lactose, starch, cellulose, sugars, and numerous APIs. That places them in scope for NFPA 660 and a dust hazard analysis (DHA), a compliance track that runs alongside cGMP and has to be designed for at the same time.